Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia.

Bekkering S, Stiekema LCA, Bernelot Moens S, Verweij SL, Novakovic B, Prange K, Versloot M, Roeters van Lennep JE, Stunnenberg H, de Winther M, Stroes ESG, Joosten LAB, Netea MG, Riksen NP.

Cell Metab. 2019 Jul 2;30(1):1-2. doi: 10.1016/j.cmet.2019.05.014. Epub 2019 Jun 13.

PMID:
31204280
2.

Familial Hypercholesterolemia.

Youngblom E, Pariani M, Knowles JW.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2014 Jan 2 [updated 2016 Dec 8].

3.

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.

Agabiti Rosei E, Salvetti M.

High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27. Review.

4.

Statins for children with familial hypercholesterolemia.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U.

Cochrane Database Syst Rev. 2017 Jul 7;7:CD006401. doi: 10.1002/14651858.CD006401.pub4. Review.

5.

Statins for children with familial hypercholesterolemia.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E.

Cochrane Database Syst Rev. 2014 Jul 23;(7):CD006401. doi: 10.1002/14651858.CD006401.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jul 07;7:CD006401.

PMID:
25054950
6.

Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment.

Maliachova O, Stabouli S.

Curr Pharm Des. 2018;24(31):3672-3677. doi: 10.2174/1381612824666181010145807.

PMID:
30317987
8.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
9.

Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).

Boytsov S, Logunova N, Khomitskaya Y; CEPHEUS II investigators.

Cardiovasc Diabetol. 2017 Dec 16;16(1):158. doi: 10.1186/s12933-017-0641-4.

10.

[Treatment with statins in children with familial hypercholesterolemia].

Kamińska E, Hennig M, Brandt A, Bautembach Minkowska J, Myśliwiec M.

Dev Period Med. 2016;20(4):328-334. Review. Polish.

11.

Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.

Zafrir B, Jubran A, Lavie G, Halon DA, Flugelman MY, Shapira C.

Eur J Prev Cardiol. 2017 May;24(8):867-875. doi: 10.1177/2047487317693132. Epub 2017 Feb 10.

PMID:
28186442
12.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
13.

Low-density lipoprotein apheresis: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1.

14.

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

Nozue T.

J Atheroscler Thromb. 2017 Sep 1;24(9):895-907. doi: 10.5551/jat.RV17012. Epub 2017 Aug 14. Review.

15.

Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Lozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug.

16.

Statins for children with familial hypercholesterolemia.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, Gylling H.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD006401. doi: 10.1002/14651858.CD006401.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD006401.

PMID:
20614444
17.

PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.

Bernelot Moens SJ, Neele AE, Kroon J, van der Valk FM, Van den Bossche J, Hoeksema MA, Hoogeveen RM, Schnitzler JG, Baccara-Dinet MT, Manvelian G, de Winther MPJ, Stroes ESG.

Eur Heart J. 2017 May 21;38(20):1584-1593. doi: 10.1093/eurheartj/ehx002.

PMID:
28329114
18.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.

Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Review.

PMID:
23754124
19.

What is new in familial hypercholesterolemia?

Santos RD, Maranhao RC.

Curr Opin Lipidol. 2014 Jun;25(3):183-8. doi: 10.1097/MOL.0000000000000073. Review.

PMID:
24699416
20.

[Diagnosis and Treatment of Familial Hypercholesterolemia].

Schöb M, Müller P, Gerth Y, Korte W, Rickli H, Brändle M, Bärlocher A, Bilz S.

Praxis (Bern 1994). 2018 Nov;107(24):1345-1353. doi: 10.1024/1661-8157/a003134. Review. German.

PMID:
30482120

Supplemental Content

Support Center